Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 13/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | MARK3 | P27448 | 1/20 | 0.33 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.33 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21685803 | 0.88 | MAP4K1 (0.48) | MAP4K1 | |
| SCHEMBL21703189 | 0.87 | MAP4K1 (0.41) | MAP4K1NR1H2 | |
| SCHEMBL25941682 | 0.87 | MAP4K1 (0.46) | MAP4K1 | |
| SCHEMBL21685654 | 0.86 | MAP4K1 (0.45) | MAP4K1NR1H2 | |
| SCHEMBL21685279 | 0.84 | MAP4K1 (0.41) | MAP4K1NR1H2 | |
| SCHEMBL21702918 | 0.84 | MAP4K1 (0.47) | MAP4K1NR1H2 | |
| SCHEMBL25941711 | 0.81 | MAP4K1 (0.48) | MAP4K1 | |
| SCHEMBL21702993 | 0.80 | MAP4K1 (0.57) | MAP4K1NR1H2 | |
| SCHEMBL21685128 | 0.79 | MAP4K1 (0.53) | MAP4K1NR1H2PDE10A | |
| SCHEMBL31303995 | 0.79 | MAP4K1 (0.53) | MAP4K1NR1H2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | MAP4K1 2520/4885NR1H2 4413/4885PIM1 4471/4885 |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | MAP4K1 2520/4885NR1H2 4413/4885PIM1 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.